Member Info for Hurst10

Friday - unit size volume stepping in-news around the corner!

The other side was done since 15.30hrs

219/ just printed

We have AVA6000 and 3996, but as the CEO mentioned, it is also about the AVA platform !!

The majors will be knocking on the door and now with Dr. Tap and the FDA working with us, it is only a matter of time before the conference in Boston.

Size buyers will have a busy 1st week in October ahead of them.

Size buying continues since presentation finished, breaking 130 level, once the market works out, what the CEO really said !!!

Spinning off Diagnostic

NYSE IPO of Therapeutics

License deal with a major

+ IPO of of Affyxell.

NY picking up more stock, after investor Q&A session.

Cohort7 already well under way!

Can we hear more about that and Dr Tap

Increase of their equity holding in Affyxell :

“This will result in an increase in Avacta's shareholding in AffyXell to approximately 25% from its current 19%, which will be determined when a formal valuation has been completed as was done for the first milestone payment.”

The 6% increase in their ownership of Affyxell, will look even more interesting for Avacta , once the IPO of the Korean company gets underway!

A great question for the company during Q&A, what value does Avacta apply to their zero cost holding?

Avacta Won best stand award at the IBMS congress 2023.

Interesting comments, keep them coming.

PS

do you have the canoccord note?

Thanks

Excellent piece of research!

Nice some good after hours buying

Just an observation: we could have 6 month’s high, by Tuesday

Up 30 % over the last month!

Let us see opening level next Thursday, but could be an interesting week ahead with further news.

Have a good week everybody.

Perhaps Monday will deliver further evidence of “ uptick in commercial interest “ in the shape of a RNS,

Pre interims!

Makes current level look very attractive before week of results.

Size buyer facing 137 upwards before noon, current working orders will be accelerated, making midday prices interesting, not surprising with figures and news next week.

NY will pick up the news and considering we only have 4 trading days before the interims and investor Q&A, could be some very lively days ahead, who knows what might happen!

The judges have completed their scoring and the Scrip Awards 2023 shortlist has now been announced! Visit our website to see who has the chance of winning a prestigious Award this year. The winners will be revealed at the ceremony on Thursday, 16 November.

BEST ONCOLOGY R&D ADVANCE *NEW*

This new Scrip Award seeks to recognize early clinical advances in oncology made by small biopharma companies. The great strides seen in cancer therapies in recent years often had their genesis in the labs of specialist firms. We are looking to reward companies that are exploiting new knowledge in cancer cell biology and the tumor microenvironment to forge new paths to tackle the disease, for instance by developing novel therapeutic strategies in immuno-oncology, gene and cell therapies and new targeted agents.

This category is aimed at clinical-stage oncology firms pioneering new approaches in the treatment of cancer that have shown proof of concept in early (Phase I or II) clinical trials and have candidates moving forward in the development pathway.

FINALISTS

AffyImmune Therapeutics’ AIC100 ICAM-1 targeting CAR T cell therapy

Arvinas and Pfizer’s oral PROteolysis TArgeting Chimera (PROTAC) ER degrader vepdegestrant for breast cancer

Avacta Therapeutics’ AVA6000 pre|CISION tumour-targeted chemotherapy

Immuneering’s deep cyclic inhibition candidate IMM-1-104 for advanced RAS-mutant solid tumors

Kura Oncology’s menin inhibitor ziftomenib for multiple genetic subsets of acute myeloid leukemia

MSD/Moderna’s mRNA-4157/V940 investigational personalized mRNA cancer vaccine.

During her career she also worked at Pfizer and Novartis!

COVID-19 Tests

Beginning September 25, every U.S. household can again place an order to receive four more free COVID-19 rapid tests delivered directly to their home. Before You Throw Out "Expired" Tests: Check to see if your COVID-19 tests' expiration dates have been extended.

The COVIDtests.gov program has distributed over 755 million tests directly to more than two-thirds of American households, 310 million of which went to households in underserved communities.